Last reviewed · How we verify

NCT04905420: PCCM-IMPACTS

The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients

Completed Last updated 31 July 2024
What this trial tests

trial in Asthma in 288,538 participants. Completed in 12 June 2023.

Timeline
8 December 2021
Primary endpoint
12 June 2023
12 June 2023

Quick facts

Lead sponsorAstraZeneca
StatusCompleted
Study typeOBSERVATIONAL
Enrollment288,538
Start date8 December 2021
Primary completion12 June 2023
Estimated completion12 June 2023
Sites1 location across China

Conditions studied

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Asthma or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Multi-centre, retrospective study describing the impact of PCCM standardized implementation on healthcare management among Asthma or COPD or Asthma-COPD overlap patients in Tianjin city of China, using real world electronic medical record database collected in local health care settings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other AstraZeneca trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04905420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing